01/09/2018

PR. BERNET APPOINTED AS KNIGHT OF THE LEGION OF HONOR

Reading : 1 minute

The President of the French Republic appointed Pr. Agnès Bernet, co-founder and CSO of NETRIS Pharma, to the highest French distinction as Knight of the Legion of Honor. The award was presented to Pr. Bernet by the former director of the Léon Berard Cancer Center, Pr. Sylvie Négrier, on January 5th 2018.

Suggested articles

logo1
12/19/2023

NETRIS Pharma extends Series A to €24.4 million and reinforces its leadership team and Board of Directors

NETRIS Pharma extends Series A to €24.4 million with €7.5 million equity injection Proceeds to enable the completion of 5 ongoing phase 2 clinical studies Reinforces its leadership team and Board of Directors

Reading : 5 min
logo Nature article
08/26/2023

Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor

Reading : 10 min
logo Nature article
08/30/2023

NETRIS Pharma announces data published in two Nature papers confirming netrin-1 blockade as significant clinical strategy in oncology

* Anti-netrin-1 monoclonal antibody, NP137, demonstrates objective response and disease stabilization as monotherapy in Phase 1 study of patients with advanced endometrial carcinoma (EC); effective in inhibiting tumor growth in several different preclinical mouse models. * Paired biopsies, pre-and-on NP137 treatment, highlight a statistically significant reduction of tumor epithelial-to-mesenchymal transition. * Netrin-1 blockade with NP137, is confirmed as a clinical strategy to alleviate resistance to standard treatments, in multiple clinical indications, including EC.

Reading : 15 min